R&D Focus: Gilead's Twice-Yearly HIV Prevention Shot Shows Promise
Thursday, 12 September 2024, 05:52
R&D Breakthrough in HIV Prevention
Gilead has announced a remarkable achievement in research and development (R&D) for HIV prevention. Their twice-yearly injection has shown effective prevention of almost all cases of HIV among 2,180 participants in a Phase 3 clinical trial.
Key Findings from the Phase 3 Study
- 98% efficacy in preventing HIV infections among participants.
- Conducted with 2,180 individuals, showcasing strong clinical results.
- Pivotal research contributes to the future of HIV prevention strategies.
As Gilead prepares for further developments, the implications of this breakthrough may reshape the landscape of HIV treatment and prevention.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.